New York, USA – August 12, 2022 – Probiotics can create bactericidal proteins (like bacteriocins) and antagonistic agents (like antibiotic-like substances) in the gut. They will also encourage the creation of metabolic end products and aid to prevent infections from a variety of pathobiont microorganisms. The importance of bacteria in human health and illness is becoming widely recognized, and mounting data suggest that a new class of live biotherapeutics made of modified microbes could target certain disease pathways. Creative Biolabs focuses on process development and optimization, as well as cGMP manufacturing, for next-generation probiotics targeting various diseases connected to the human microbiome.
Live biotherapeutic products (LBPs), also known as NGPs, are helpful bacteria that may not only be generated as traditional probiotics merely as foods or dietary supplements, but also as organisms designed for medicinal use. It has been demonstrated that NGPs target particular disorders and function therapeutically like medications. Creative Biolabs specializes in delivering process development & optimization and cGMP manufacturing services for NGPs addressing various disorders associated with the human microbiome on the basis of knowledge in microbiota and microbiome research. Common next-generation probiotics include Akkermansia muciniphila, Streptococcus spp., and Christensenella minuta.
A symbiotic bacteria of the mucus layer, Akkermansia muciniphila, is a member of the phylum Verrucomicrobia. A. muciniphila colonization and abundance in the gut are linked to host health and disease. Many studies have linked A. muciniphila abundance to a variety of diseases, including metabolic syndromes, autoimmune diseases, cardiometabolic diseases, gastrointestinal disorders, and cancer. Through NGP development services, Creative Biolabs can thoroughly investigate the preclinical and commercial value of developing A. muciniphila.
A recently discovered gut bacteria called Christensenella minuta is crucial in avoiding obesity. Furthermore, a growing body of research points to C. minuta’s probiotic potential and prospective therapeutic use in the treatment of obesity and associated gastrointestinal problems. Creative Biolabs offers a wide variety of top-notch services and assistance for the Christensenella minuta probiotics development.
Streptococcus thermophilus, Streptococcus dentisan, and Streptococcus salivarius are three likely streptococcus species that are capable of stopping the progression of diseases like chronic kidney disease and upper respiratory tract infections as well as reducing the frequency with which their infections manifest. By offering precise equipment and accredited reagents, Creative Biolabs supports the study and development of NGPs and ensures stable and trustworthy results for every test.
Visit the page for additional details about Creative Biolabs’ NGP discovery services: https://live-biotherapeutic.creative-biolabs.com.
About Creative Biolabs
As a biotechnology company keeping pace with the technological innovations, Creative Biolabs has invested much energy and effort in the identification and discovery of new NGPs. Creative Biolabs now provides a full range of probiotics-based drug discovery services for related diseases.